Mexico: Crossed Wires: Protecting Medicines In Mexico

Last Updated: 30 June 2015
Article by Daniel Sánchez and Víctor Ramírez

Trademark registration system

Trademarks in Mexico are regulated under the Industrial Property Law (IPL) and its regulations. In general, businesses, merchants, or service providers can use trademarks in industry, commerce or in the services they render (Article 87, IPL). The right to their exclusive use is obtained through their registration with the Mexican Institute of Industrial Property (IMPI). Any person or entity is entitled to apply for a trademark registration before the IMPI, and actual use is not required by the IPL.

All visible signs can be protected provided that they are sufficiently distinctive, and are able to identify the products or services to which they are applied, or are intended to be applied, from those in the same class (Article 89, IPL). Under this definition, olfactory and auditory trademarks cannot be protected.

However, three-dimensional signs can be protected as trademarks since these are visible signs. What cannot be protected as a trademark is set out in a rather long article (Article 90, IPL), which contains a list of general prohibitions and the only legal grounds for rejecting a trademark application.

In addition to the general, absolute and relative prohibitions provided in the IPL, in the case of brands related to medicinal products, Mexican trademark examiners have a special rule regarding registrability based on the Mexican Health Law (MHL): if a junior trademark application does not have at least a three-letter difference from a senior trademark registration, and is confusingly similar, the junior one will not be registered.

Even though the MHL is not binding for trademark matters as it is not included in the IPL, Mexican examiners use their discretion to apply it.

As well as this special criterion, when applying for a trademark registration, applicants must bear in mind that medicinal products fall into class 5, which includes many other types of goods that are unrelated, such as baby foods, disinfectants, fungicides and herbicides.

This should not be a problem as long as a junior trademark application is refused only if it is confusingly similar to a senior trademark registration and the goods sought to be protected are the same as, or related to, ones covered by the older trademark registration.

However, as mentioned above, actual use of a trademark in the Mexican market is not a requirement to apply for, or get, trademark protection, so in domestic practice any applicant may request the broadest protection possible— that is, all the products that are covered in a single class.

Therefore, when choosing a trademark in Mexico for a medicinal product, the applicant needs to make a careful and deep search, bearing in mind all the peculiarities of the Mexican system, to evaluate the possibilities of achieving trademark rights.

Obtaining a trademark registration does not, however, automatically mean that trademark owner is able actually to use the trademark on medicinal products. There is yet another process that involves a different authority, and has its own characteristics.

Health authorisation process

According to our legal system, the process to obtain marketing authorisation from the Federal Commission for Protection against Sanitary Risks (COFEPRIS) of the Mexican Health Authority for a medicinal product includes a review and approval for the pharmaceutical or drug name, referred to by our regulatory bodies as a 'distinctive name'. Failure to propose an acceptable name will result in a bar to obtaining marketing authorisation.

The specific requirements and rules regarding distinctive names are provided under the MHL and its regulations. The basic set of rules regarding the pharmaceutical or drug names is as follows:

  • The term distinctive name will be understood as the name or trademark assigned by the laboratory or manufacturer to its pharmaceutical products, in order to distinguish it from other similar products, and prior approval of the health authority and registration with the competent authorities is required (Section IV, Article 2 MHL Regulations);
  • Medications for use and marketing will be identified by their distinctive and generic names. Generic identification is required (Article 225 MHL);
  • The distinctive name must not make clear, or unclear, reference to the composition of the medicinal product or its therapeutic action. No indications are permitted in relation to diseases, syndromes, symptoms, nor anatomical data or physiological phenomena, except for vaccines and biological products (Article 225 MHL);
  • A proposed distinctive name can be rejected when it is confusingly similar to a prior authorised drug name, in which case the difference between the proposed and the prior drug name should be at least three letters in each word (Article 23 MHL Regulations);
  • A distinctive name will also be rejected if the proposal is identical to a prior distinctive name of another drug with existing health registration (Article 23 MHL Regulations); and
  • The same distinctive name should be used only in the case of different pharmaceutical forms or different doses with the same principal active ingredient and registered by the same laboratory (Article 23 MHL Regulations).

Although a legal definition of a distinctive name is provided under Section IV, Article 2 of the MHL Regulations—including that it is subject to the approval of the corresponding authorities— in practice, prior approval and registration with other relevant agencies, such as IMPI, is not required for the application and granting of the distinctive name before COFEPRIS. In fact, having a trademark registration for the distinctive name will not make any difference for the purposes of getting a marketing authorisation with that trademark.

COFEPRIS decisions regarding medicinal products are completely independent from what the IMPI may decide regarding distinctive names, which of course are trademarks according to the IPL.

Unfortunately, there is not yet a clear and specific link between the IPL, the MHL and the MHL regulations (the HLR) regarding conflicts between registered trademarks and marketing authorisations/distinctive names.

As mentioned, IMPI examiners usually take into consideration the 'three letters' rule when analysing the similarity of trademarks for pharmaceutical products, though this rule (provided by the HLR) is not binding for IMPI Examiners.

On the other hand, COFEPRIS is not bound by the HLR to consider senior trademark registrations (for pharmaceutical products) when analysing the similarity of distinctive names by means of their own tool: software developed to apply the three letters rule.

This situation causes undesirable scenarios such as contrary decisions issued by IMPI and COFEPRIS regarding the likelihood of confusion for the same trademarks and distinctive names.

Furthermore, IMPI and COFEPRIS have different databases. The IMPI database comprises all the trademark applications and registrations that have been filed with the agency or its predecessors. The COFEPRIS database contains only all the distinctive names allowed for medicinal products, regardless of whether the distinctive names are currently in use.

Marketing authorisations used to be granted for an unlimited period of time, until amendments in 2008 to the HLR.

Since those amendments came into force, marketing authorisations have been granted for renewable, five-year periods. Marketing authorisations granted before the amendments should have been renewed before February 2010. It is not yet clear whether COFEPRIS will remove the distinctive names for authorisations that have not been renewed. In this scenario, a trademark infringement could be triggered by companies that have a marketing authorisation but cannot achieve trademark rights because of the different criteria and the different databases used by the two agencies.

A third difference is found between IMPI and COFEPRIS when dealing with medicinal trademarks. During IMPI's procedure, the applicant may file arguments and request limitation of third party rights, whereas during the COFEPRIS procedure for marketing authorisation, the applicant will not know why its distinctive name has been rejected.

Due to this lack of clarity, from 2010, COFEPRIS has offered pharmaceutical companies the possibility of obtaining a pre-approval through its website. If a three-letter coincidence is detected, the proposed name will be rejected.

If the distinctive name is approved, the system will grant the user a certificate that will last for 90 days and can be used by the applicant for any marketing authorisation. The COFEPRIS system allows users to have up to 10 valid certificates for distinctive names that can be used by the company at any time while the certificates are valid. Once a certificate expires, the user is allowed to obtain new certificates.

However, these pre-approval certificates are not binding and COFEPRIS may still reject the distinctive name during the marketing authorisation procedure. Although a rejection of this type may be challenged before the courts, this almost never happens.

Mexico needs a trademark linkage system between COFEPRIS and IMPI. Some attempts to do it have been proposed to Congress in the past without success. The idea around these proposals is to require applicants to obtain a trademark registration from IMPI first, leaving COFEPRIS the authority to deny marketing authorisation when the proposed trademark indicates diseases, syndromes, symptoms, anatomical data or physiological phenomena.

In May 2012, the Mexican Senate gave notice that Mexico has joined the Madrid Protocol for trademark registration. The implications of this treaty are yet to be studied, but this change in the Mexican policy on trademarks could provide the momentum to implementing a trademark linkage system.

Originally published Apr-01-2013. Source: Life Sciences Intellectual Property Review 2012

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.